Cantor Fitzgerald Reiterates Overweight on Gilead After Positive HIV Trial
Cantor Fitzgerald reiterated its Overweight rating on Gilead Sciences (GILD) with a $155 price target on June 9, after the company reported positive phase 3 HIV trial results in collaboration with Merck.
Key Numbers
On June 9, Cantor Fitzgerald reiterated its Overweight rating on Gilead Sciences (NASDAQ: GILD) with a $155 price target, following the announcement of positive top-line results from a phase 3 clinical trial for an HIV treatment developed in collaboration with Merck.
Rating Change
The rating and price target were reaffirmed, not changed. Cantor Fitzgerald maintained its Overweight rating and $155 target, signaling confidence in the stock's prospects.
Analyst Rationale
The analyst cited the strong phase 3 results from the Gilead-Merck HIV trial. The data showed high efficacy, which could support regulatory approval and market expansion.
Context
Gilead is a leader in HIV therapeutics. The stock has been volatile over the past year. Other analysts are closely watching, as trial success could reshape the competitive landscape. The current price target of $155 implies about 20% upside from recent trading levels.
Conclusion
The reiterated rating reflects analyst optimism about Gilead's pipeline, especially the promising HIV trial. However, investors should monitor regulatory decisions and market competition.
Frequently Asked Questions
Found this useful? Share it